Morningstar

Aldeyra Therapeutics Inc ALDX

Morningstar Rating

Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment

Global News Select Oct 3, 2024 12:42pm
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Business Wire Oct 3, 2024 11:00am
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire Sep 5, 2024 11:00am
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Business Wire Aug 8, 2024 11:00am
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Business Wire Aug 7, 2024 8:01pm
Aldeyra Therapeutics Says Additional Trial Needed For FDA Approval of Dry-Eye Disease Treatment

Global News Select Nov 27, 2023 9:50pm
Aldeyra Shares Continue to Rally After AbbVie Agrees to Licensing Option

Global News Select Nov 1, 2023 6:12pm
Aldeyra Shares Rally After AbbVie Licensing Deal on Eye Drug

Global News Select Nov 1, 2023 12:33pm
Aldeyra Therapeutics stock plunges on heavy volume after FDA finds 'substantive' issues with NDA for dry-eye disease treatment

MarketWatch Oct 16, 2023 3:50pm
Aldeyra Therapeutics Shares Fall 73% After Warning That FDA Might Not Approve Drug

Global News Select Oct 16, 2023 1:25pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.